Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers.

ABSTRACT:

Introduction

We evaluated a panel of novel urinary and serum biomarkers (BMs) for early and sensitive detection of cisplatin drug-induced kidney injury (DIKI) in patients with cancer, comparing their diagnostic accuracy with standard BMs (SBMs).

Methods

In this prospective exploratory observational study, 105 patients treated with cisplatin ("treated" with > 65 mg/m²/cycle), 20 non-cisplatin treated cancer controls ("nontreated"), and 34 "healthy" controls were enrolled. The treated group's serum and urine samples were collected predose, after 12 hours, and on days 1, 2, 4, 7, 14, and 21. SBMs and novel BMs (NBMs; 8 urinary, 1 serum) were measured, comparing accuracy, percent changes from baseline (PCFBs), and median time to peak values between treated patients an

SUBMITTER: Strader M 

PROVIDER: S-EPMC12034874 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature